BLU-667 Targets RET-Altered Cancers
- PMID: 29657136
- DOI: 10.1158/2159-8290.CD-NB2018-050
BLU-667 Targets RET-Altered Cancers
Abstract
Findings from a phase I study indicate that the investigational RET inhibitor BLU-667 is safe and well tolerated, inducing good responses in patients with RET-altered medullary thyroid cancer or non-small cell lung cancer.
©2018 American Association for Cancer Research.
Comment on
-
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15. Cancer Discov. 2018. PMID: 29657135
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
